This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2012 Feb;13(2):e51; author reply e51.

doi: 10.1016/S1470-2045(12)70056-6.

A STEPP too far for FLEX?

Emmanuel Bergot, Christian Creveuil, Gérard Zalcman

PMID: 22300858
DOI: 10.1016/S1470-2045(12)70056-6

Comment

A STEPP too far for FLEX?

Emmanuel Bergot et al. Lancet Oncol. 2012 Feb.

. 2012 Feb;13(2):e51; author reply e51.

doi: 10.1016/S1470-2045(12)70056-6.

Authors

Emmanuel Bergot, Christian Creveuil, Gérard Zalcman

PMID: 22300858
DOI: 10.1016/S1470-2045(12)70056-6

No abstract available

PubMed Disclaimer

Comment on

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.
Pirker R, Pereira JR, von Pawel J, Krzakowski M, Ramlau R, Park K, de Marinis F, Eberhardt WE, Paz-Ares L, Störkel S, Schumacher KM, von Heydebreck A, Celik I, O'Byrne KJ. Pirker R, et al. Lancet Oncol. 2012 Jan;13(1):33-42. doi: 10.1016/S1470-2045(11)70318-7. Epub 2011 Nov 4. Lancet Oncol. 2012. PMID: 22056021 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information